Provinciali M, Di Stefano G, Stronati S, Raffaeli W, Pari G, Fabris N
Immunology Center, INRCA Gerontology Research Dept., Ancona, Italy.
Int J Immunopharmacol. 1996 Oct;18(10):577-86. doi: 10.1016/s0192-0561(96)00059-8.
In a previous work we demonstrated that chronic in vivo antalgic therapy of cancer patients with morphine reduced the endogenous cytotoxic activity of natural killer (NK) cells, while increasing the development of lymphokine activated killer (LAK) cell cytotoxicity. In order to investigate the mechanisms by which morphine affects NK and LAK cell function further, we evaluated the modulation exerted by short- or long-term morphine administration on either NK/LAK cell cytotoxicities or plasma levels of prolactin (PRL) and other immunomodulating neurohormones. An intravenous morphine injection (10 mg) significantly increased the plasma levels of PRL, reduced the cytotoxic activity of NK cells, and increased the development of LAK cell activity 30 min after drug injection in neoplastic patients. The administration of bromocriptine before the injection of morphine prevented both PRL augmentation and the increase in LAK cell activation, although it did not prevent the inhibition of NK cytotoxicity. The chronic oral administration of morphine (90 +/- 30 mg/day for 1 month) also resulted in higher PRL levels; the NK and LAK cell activities were, respectively, lower than or higher than those found in neoplastic patients untreated with morphine. The plasma levels of thyrotropin (TSH), adrenocorticotropic hormone (ACTH) and cortisol were not significantly modified in either short- or long-term experiments. The absolute number and the percentages of lymphocyte populations, as well as the percentage of IL-2 receptors, were not modified after short-term morphine administration whereas little changes of T lymphocyte populations and NK cell number were observed after oral treatment with morphine. In vitro morphine did not affect the development of LAK cell activity. In conclusion, our findings indicate that morphine reduces NK cytotoxicity and increases the development of LAK cell cytotoxicity after short- and long-term administration. The effect of morphine on LAK cell activation but not on NK cell reduction is related to the modulation of PRL levels determined by the opioid drug.
在之前的一项研究中,我们证实,癌症患者长期接受吗啡的体内镇痛治疗会降低自然杀伤(NK)细胞的内源性细胞毒性活性,同时增强淋巴因子激活的杀伤(LAK)细胞的细胞毒性。为了进一步研究吗啡影响NK和LAK细胞功能的机制,我们评估了短期或长期给予吗啡对NK/LAK细胞毒性或催乳素(PRL)及其他免疫调节神经激素血浆水平的调节作用。静脉注射吗啡(10毫克)可显著提高肿瘤患者注射药物30分钟后血浆PRL水平,降低NK细胞的细胞毒性活性,并增强LAK细胞活性。在注射吗啡前给予溴隐亭可防止PRL升高和LAK细胞激活增加,尽管它不能防止NK细胞毒性的抑制。长期口服吗啡(90±30毫克/天,持续1个月)也会导致PRL水平升高;NK和LAK细胞活性分别低于或高于未接受吗啡治疗的肿瘤患者。在短期或长期实验中,促甲状腺激素(TSH)、促肾上腺皮质激素(ACTH)和皮质醇的血浆水平均未发生显著变化。短期给予吗啡后,淋巴细胞群体的绝对数量和百分比以及IL-2受体的百分比均未改变,而口服吗啡治疗后观察到T淋巴细胞群体和NK细胞数量有轻微变化。体外实验中,吗啡不影响LAK细胞活性的发展。总之,我们的研究结果表明,短期和长期给予吗啡后,吗啡会降低NK细胞毒性并增强LAK细胞毒性。吗啡对LAK细胞激活而非NK细胞减少的影响与阿片类药物对PRL水平的调节有关。